DE4447484C2 - Mittel zur Hemmung von Apoptose - Google Patents
Mittel zur Hemmung von ApoptoseInfo
- Publication number
- DE4447484C2 DE4447484C2 DE4447484A DE4447484A DE4447484C2 DE 4447484 C2 DE4447484 C2 DE 4447484C2 DE 4447484 A DE4447484 A DE 4447484A DE 4447484 A DE4447484 A DE 4447484A DE 4447484 C2 DE4447484 C2 DE 4447484C2
- Authority
- DE
- Germany
- Prior art keywords
- apo
- compound
- tat
- receptor
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4447484A DE4447484C2 (de) | 1994-04-08 | 1994-04-08 | Mittel zur Hemmung von Apoptose |
| DE19944412177 DE4412177C1 (de) | 1994-04-08 | 1994-04-08 | Hemmer von Apoptose |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4447484A DE4447484C2 (de) | 1994-04-08 | 1994-04-08 | Mittel zur Hemmung von Apoptose |
| DE19944412177 DE4412177C1 (de) | 1994-04-08 | 1994-04-08 | Hemmer von Apoptose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE4447484A1 DE4447484A1 (de) | 1995-10-26 |
| DE4447484C2 true DE4447484C2 (de) | 1997-07-17 |
Family
ID=6514949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE4447484A Expired - Lifetime DE4447484C2 (de) | 1994-04-08 | 1994-04-08 | Mittel zur Hemmung von Apoptose |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20070207160A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP0705278B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP3778453B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE255129T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE4447484C2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0705278T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2211899T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1995027735A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2215905A1 (en) | 1995-03-20 | 1996-09-26 | Sumitomo Electric Industries, Ltd. | Monoclonal antibody reacting specifically with fas ligand and process for producing the same |
| AU6091496A (en) * | 1995-06-07 | 1996-12-30 | Chiron Corporation | Antibodies to fas antigen capable of inhibiting apoptosis |
| US6096312A (en) * | 1995-06-30 | 2000-08-01 | Mochida Pharmaceutical Co., Ltd. | Agent for suppressing a reduction of CD4+ lymphocytes |
| JPH09124509A (ja) * | 1995-10-27 | 1997-05-13 | Sumitomo Electric Ind Ltd | 肝炎治療剤 |
| DE19544333C2 (de) * | 1995-11-28 | 1998-12-10 | Deutsches Krebsforsch | Verfahren zur Beurteilung der Aktivität von Arzneistoffen |
| WO1997039722A2 (en) * | 1996-04-25 | 1997-10-30 | T Cell Sciences, Inc. | Method of isolating regulators of t cell activation |
| GB9703276D0 (en) * | 1997-02-17 | 1997-04-09 | Screaton Gavin R | Materials and methods relating to the protection of useful immune cells |
| EP1025242A1 (en) * | 1997-10-30 | 2000-08-09 | Cornell Research Foundation, Inc. | A method of inhibiting an immune response to a recombinant vector |
| EP1447093A1 (en) | 2003-02-14 | 2004-08-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries |
| WO2004085479A2 (en) | 2003-03-26 | 2004-10-07 | Apogenix Gmbh | Treatment of viral infections |
| US9309320B2 (en) | 2006-12-28 | 2016-04-12 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo |
| EP2310409A2 (en) | 2008-06-17 | 2011-04-20 | Apogenix GmbH | Multimeric tnf receptors |
| CN102497886B (zh) * | 2009-07-21 | 2016-01-20 | 玛丽皇后与斯特菲尔德学院 | 用于细胞内药物递送的Fas(Apo-1,CD95)靶向平台 |
| JP6297552B2 (ja) | 2012-07-18 | 2018-03-20 | アポジェニックス アーゲー | Mdsの治療のための、cd95シグナル伝達経路阻害剤 |
| EP3076179A1 (en) | 2015-03-30 | 2016-10-05 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Diagnosis and treatment of low grade gliomas |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| AU2018205234B2 (en) | 2017-01-06 | 2024-09-19 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists |
| ES3055314T3 (en) | 2017-01-06 | 2026-02-11 | Iovance Biotherapeutics Inc | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| WO2018209115A1 (en) | 2017-05-10 | 2018-11-15 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| JP2021503885A (ja) | 2017-11-22 | 2021-02-15 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 末梢血からの末梢血リンパ球(pbl)の拡大培養 |
| EP3724885A2 (en) | 2017-12-15 | 2020-10-21 | Iovance Biotherapeutics, Inc. | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof |
| CA3090795A1 (en) | 2018-02-13 | 2019-08-22 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists |
| SG11202109331QA (en) | 2019-03-01 | 2021-09-29 | Iovance Biotherapeutics Inc | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| CN114269370A (zh) | 2019-03-29 | 2022-04-01 | 迈斯特治疗公司 | 离体产生t细胞治疗剂的方法以及相关的组合物和方法 |
| IL293350A (en) | 2019-11-27 | 2022-07-01 | Myst Therapeutics Llc | Method of producing tumor-reactive t cell composition using modulatory agents |
| EP4110799B1 (en) | 2020-02-27 | 2024-11-06 | Turnstone Biologics Corp. | Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof |
| US20260124242A1 (en) | 2022-11-04 | 2026-05-07 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| WO2026044087A1 (en) | 2024-08-21 | 2026-02-26 | Shape Therapeutics Inc. | Increased cellular stability for aav production |
| WO2026073032A1 (en) | 2024-09-27 | 2026-04-02 | Shape Therapeutics Inc. | Constructs for improved aav production |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4486344A (en) * | 1983-03-28 | 1984-12-04 | Miles Laboratories, Inc. | Urea-linked immunogens, antibodies, and preparative method |
| DK354487A (da) * | 1986-07-11 | 1988-01-12 | Noboru Yanaihara | Oncogen-relaterede peptider |
| PT90657B (pt) * | 1988-05-27 | 1995-03-01 | Ortho Pharma Corp | Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora |
| EP0522081A4 (en) * | 1990-03-30 | 1993-06-16 | Smithkline Beecham Corporation | Inhibition of disease associated with immunodeficiency virus infection |
| CA2067031C (en) * | 1991-04-26 | 2003-02-18 | Shigekazu Nagata | Dna coding for human cell surface antigen |
| US5830469A (en) * | 1993-10-14 | 1998-11-03 | Immunex Corporation | Fas antagonists and uses thereof |
| NZ275711A (en) * | 1993-10-14 | 1998-03-25 | Immunex Corp | Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type) |
-
1994
- 1994-04-08 DE DE4447484A patent/DE4447484C2/de not_active Expired - Lifetime
-
1995
- 1995-02-16 DK DK95909730T patent/DK0705278T3/da active
- 1995-02-16 EP EP95909730A patent/EP0705278B1/de not_active Expired - Lifetime
- 1995-02-16 ES ES95909730T patent/ES2211899T3/es not_active Expired - Lifetime
- 1995-02-16 WO PCT/EP1995/000573 patent/WO1995027735A1/de not_active Ceased
- 1995-02-16 JP JP52603195A patent/JP3778453B2/ja not_active Expired - Lifetime
- 1995-02-16 AT AT95909730T patent/ATE255129T1/de not_active IP Right Cessation
-
2004
- 2004-03-09 JP JP2004064978A patent/JP3811745B2/ja not_active Expired - Lifetime
-
2007
- 2007-02-14 US US11/705,956 patent/US20070207160A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE255129T1 (de) | 2003-12-15 |
| US20070207160A1 (en) | 2007-09-06 |
| JP3778453B2 (ja) | 2006-05-24 |
| DE4447484A1 (de) | 1995-10-26 |
| WO1995027735A1 (de) | 1995-10-19 |
| JP2004215669A (ja) | 2004-08-05 |
| JP3811745B2 (ja) | 2006-08-23 |
| EP0705278B1 (de) | 2003-11-26 |
| EP0705278A1 (de) | 1996-04-10 |
| ES2211899T3 (es) | 2004-07-16 |
| JPH08511692A (ja) | 1996-12-10 |
| DK0705278T3 (da) | 2004-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0705278B1 (de) | Hemmer von apoptose | |
| DE69433422T2 (de) | Monoklonaler anti-hiv antikörper | |
| DE69229428T2 (de) | Therapeutisch nützliche peptide und peptidfragmente | |
| DE69330643T2 (de) | Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon | |
| DE69522216T2 (de) | Zielzellen-bindende chimäre Peptide | |
| DE69431834T2 (de) | Für den vorläufer des für die tumorabstossung verantwortlichen antigens mage-3 kodierendes, isoliertes nukleinsäuremolekül und seine verwendung | |
| DE69129896T2 (de) | Gegen cd3 gerichtete antikörper | |
| DE69233435T2 (de) | Vorläufer von für tumorabstossung verantwortlichen antigenen, die antigene und deren verwendungen | |
| DE60133029T2 (de) | Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff | |
| DE69624436T2 (de) | Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie | |
| DE69017753T2 (de) | Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper. | |
| DE69334186T2 (de) | Vom MAGE-3-Gen en abgeleitetes und von HLA-A1 präsentiertes, isoliertes Nonapeptid und dessen Anwendungen | |
| DE69429095T2 (de) | Humanisierte antikoerper | |
| DE3888379T2 (de) | Leukämie hemmender Faktor. | |
| EP0657533A1 (de) | Monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen, sowie bispezifische monoklonale Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD-30-HRS-3-Antikorpers | |
| DE69230206T2 (de) | Rekombinante derivate des menschlichen faktors viii | |
| WO1999015553A2 (de) | Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung | |
| EP1003786A1 (de) | Peptid mit radioprotektiver wirkung | |
| DE69131426T2 (de) | Neue wasserlösliche polypeptide mit hoher affinität für alpha- und beta- interferone | |
| DE69636170T2 (de) | Monoklonaler antikörper, der spezifisch mit dem fas-liganden reagiert, und verfahren zu seiner herstellung | |
| DE68925199T2 (de) | Peptide und polypeptide stammend von den submaxillaren drüsen der ratte, deren entsprechende monoklonale und polyklonale antikörper entsprechende hybridomen und verwendung dieser verbindungen in der diagnose bei bestimmungen und für pharmazeutische zwecke | |
| DE69420251T2 (de) | Löslicher Interferon-Rezeptor, seine Herstellung und Anwendung | |
| DE69031914T2 (de) | Rezeptor für granulozyten-macrophagen-koloniestimulierungsfaktor und seine derivate | |
| WO2001051644A2 (de) | ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN Cν3- und Cν4- DOMÄNEN | |
| DE69020112T2 (de) | Spezifische bindende Wirkstoffe. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AC | Divided out of |
Ref country code: DE Ref document number: 4412177 Format of ref document f/p: P |
|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| AC | Divided out of |
Ref country code: DE Ref document number: 4412177 Format of ref document f/p: P |
|
| AC | Divided out of |
Ref country code: DE Ref document number: 4412177 Format of ref document f/p: P |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| R071 | Expiry of right | ||
| R071 | Expiry of right |